bioAffinity Technologies, Inc. (BIAFW) stock
BIAFWNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31Also trades as BIAF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 4/3056% below fair value
$0.24+0.00 (0.00%)
Close on Oct 30, 2026Market cap $23.58MP/E –Yield –
bioAffinity Technologies free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
bioAffinity Technologies's free cash flow for the twelve months ending Jun 30, 2026 was -$11.56M. For fiscal 2025 it was -$9.39M.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$9.39M | – |
| FY2024 | Dec 31, 2024 | -$7.34M | – |
| FY2023 | Dec 31, 2023 | -$6.06M | – |
| FY2022 | Dec 31, 2022 | -$4.29M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$3.29M | – |
| Q1 FY2026 | Mar 31, 2026 | -$3.23M | – |
| Q4 FY2025 | Dec 31, 2025 | -$2.56M | – |
| Q3 FY2025 | Sep 30, 2025 | -$2.48M | – |
| Q2 FY2025 | Jun 30, 2025 | -$2.66M | – |
| Q1 FY2025 | Mar 31, 2025 | -$1.69M | – |
| Q4 FY2024 | Dec 31, 2024 | -$1.68M | – |
| Q3 FY2024 | Sep 30, 2024 | -$1.72M | – |
| Q2 FY2024 | Jun 30, 2024 | -$1.56M | – |
| Q1 FY2024 | Mar 31, 2024 | -$2.39M | – |
| Q4 FY2023 | Dec 31, 2023 | -$1.60M | – |
| Q3 FY2023 | Sep 30, 2023 | -$1.53M | – |
| Q2 FY2023 | Jun 30, 2023 | -$1.36M | – |
| Q1 FY2023 | Mar 31, 2023 | -$1.56M | – |